The investable story in Serbia’s private medical market is no longer just that patients are paying to avoid public-sector waiting lists. It is that private healthcare is becoming a platform sector: branded hospital networks, outpatient clinics, diagnostics, laboratories, imaging, day surgery, corporate health plans, insurer contracts, employer benefits and eventually digital patient-data infrastructure. That is why Serbia now sits at the intersection of two meanings of “equity”: equity capital moving into private healthcare assets, and healthcare equity as a public-policy concern in a country where out-of-pocket spending remains structurally high.
Serbia’s public system is still the core of national healthcare. Compulsory health insurance covers almost the whole population, with the National Health Insurance Fund acting as the main purchaser. But the pressure point is financial protection. WHO’s Serbia health-system profile states that out-of-pocket payments accounted for 35.8% of current health expenditure in 2021, far above the level seen in many EU systems, while voluntary health insurance was still below 1% of current health spending at that point. That creates a classic private-market opening: patients remain nominally covered by the public system, yet many still pay privately for speed, specialist access, diagnostics, medicines or perceived quality.
The Competition Commission of Serbia’s 2025 sector inquiry captured the same structural shift. It found that Serbia has a “significant and growing” private healthcare sector, driven by faster appointment scheduling, shorter waiting times, better treatment conditions, modern equipment and the expansion of employer-funded private health insurance. The Commission also noted that voluntary health insurance’s share of non-life insurance premiums increased from 6% in 2019 to 12% in 2023, which is one of the clearest signals that demand is moving from pure cash-pay medicine toward contracted, institutionalised demand.
That matters for investors because insurance-linked healthcare is more scalable than isolated private consultations. A clinic that depends only on walk-in payments has local-catchment economics. A network linked to insurers and employers can build recurring volume, standardised pricing, centralised procurement, diagnostic cross-referrals and data-driven patient retention. In that model, the equity story is not simply “buy hospitals”; it is “control the patient pathway”.
The market is already concentrated around a few visible platforms. The Competition Commission analysed 18 market participants that owned 29 private institutions, including 16 general hospitals and 13 health centres. That sample represented around 60% of private general hospitals and health centres in Serbia and about 40–50% of total private healthcare revenues, meaning the formal hospital-and-centre segment is already platform-shaped even though the wider market remains fragmented across laboratories, pharmacies, specialist practices and smaller clinics.
Belgrade is the centre of gravity. More than 30% of private health centres and more than 70% of private general hospitals are located in the capital, according to the Commission. Total revenues of private healthcare institutions in Serbia reached about RSD 34bn in 2022, up 54% compared with 2019, with the strongest annual jump in 2021, when Covid-era demand accelerated the turn toward private providers.
The leadership group is clear: MediGroup, Bel Medic/Acibadem Bel Medic and Euromedik. The Commission stated that the three largest systems accounted for about 80% of revenues among the observed participants, while their individual revenue growth between 2019 and 2023 ranged from 47% to 143%. The exact 2023 revenue figure was redacted in the official sector analysis, but the Commission said the observed participants’ revenues had almost doubled over the five-year period.
This explains why private equity and strategic capital have already entered. MediGroup became one of the key proof points. MidEuropa invested in 2018, supported add-on acquisitions and expansion, and later integrated the business with Romania’s Regina Maria platform. MidEuropa says MediGroup had more than 1m patients per year, completed five add-on acquisitions, expanded into inpatient care, outpatient care, laboratories, IVF, ophthalmology and other segments, and increased employee numbers by around 40% since 2021.
The next stage was even more telling. In 2025, Mehiläinen, backed by CVC and Hellman & Friedman, completed the acquisition of Regina Maria and MediGroup, creating a regional healthcare platform. CVC described MediGroup as Serbia’s leading private healthcare provider, with 100 units and more than 2,500 employees, while the combined Regina Maria–MediGroup business generated around €550m in revenue in 2024.
That transaction changes how Serbia should be read by investors. Serbia is no longer merely a domestic private-clinic market. It is part of a regional healthcare consolidation map linking Serbia, Romania and broader CEE healthcare infrastructure. For private equity, the playbook is familiar: buy or build a platform, consolidate clinics and diagnostics, attach corporate-insurance volume, improve utilisation, centralise procurement, professionalise management and then sell to a larger strategic or financial sponsor. MediGroup shows that this exit route is already viable.
Acibadem Bel Medic represents the strategic-hospital-chain model. Bel Medic became part of the Acibadem network in 2021, connecting Serbia to Turkey’s IHH/Acibadem hospital system. The Belgrade platform includes a hospital and medical centres, with inpatient capacity, operating rooms, intensive care, diagnostics and specialist services. This is a different equity thesis from MediGroup: less a pure PE roll-up, more a cross-border hospital-brand and medical-tourism play, with Serbia positioned inside a wider regional health-services corridor.
Euromedik is the domestic counterweight. It remains one of the most important Serbian-origin private healthcare platforms, with a broad outpatient and diagnostic footprint. Public business-profile data for 2024 described Euromedik as employing more than 1,120 people, including about 400 specialist doctors, and conducting more than 1.63m examinations across 17 facilities. Its growth shows that foreign capital is not the only route to scale; local entrepreneurial healthcare platforms can still compete where brand, location density, specialist access and patient trust are strong.
The next investable layer is insurance. Voluntary health insurance in Serbia is still small relative to the total health system, but it is becoming highly relevant inside the private medical economy. The Competition Commission found that voluntary health insurance premiums increased almost 3.5 times from 2019 to 2023, while legal entities and employers accounted for more than 90% of premium. It also found that around 60% of insurer payments to private healthcare institutions over five years went to MediGroup, Euromedik and Bel Medic.
The National Bank of Serbia’s 2025 insurance-sector report confirms that health insurance is becoming a larger part of the insurance market. Total insurance premiums reached RSD 191.5bn in 2025, up 8.0%, while voluntary health insurance premiums rose 16.5% and increased their share of total premiums from 9.9% in 2024 to 10.7% in 2025. Three insurers controlled 64.8% of the voluntary health insurance segment.
For equity investors, this is important because the strongest private providers are becoming semi-infrastructure assets. They do not have concession contracts or regulated returns, but they increasingly sit between employers, insurers and households. A private healthcare platform with dense locations in Belgrade, Novi Sad, Niš and larger industrial centres can become a preferred provider for corporate Serbia: banks, IT companies, manufacturing exporters, logistics groups, foreign investors and public-sector-adjacent employers that use private health benefits to retain staff.
The strongest entry points are likely to be diagnostics, laboratory services, occupational medicine, specialist outpatient networks, fertility, ophthalmology, oncology screening, cardiology, imaging and day surgery. These are areas where patients value speed, employers value productivity, insurers can structure packages, and providers can build repeat volume without the full capital burden of large tertiary hospitals. Full-service hospitals remain strategically attractive, but they are heavier CAPEX assets, more exposed to specialist-labour scarcity and more sensitive to utilisation risk.
The constraint is medical labour. The Commission’s observed participants employed 1,123 doctors in 2023, up 43% from 2019, while doctors engaged outside employment numbered 2,120. Medical staff rose 55% and non-medical staff 70%, while 15 participants reported around 4.3m examinations in 2023, up 55% compared with 2019. That is rapid institutional growth, but it also points to the bottleneck: the market can open new locations faster than it can create senior physicians, nurses and technicians.
The healthcare-equity issue is therefore not separate from the investment case. Serbia’s private medical market grows because the public system leaves demand unresolved. That creates commercial opportunity, but it also risks deepening a two-speed system: insured corporate employees and middle-income urban households receive faster private access, while lower-income households remain more exposed to medicines, co-payments and delays. WHO data show that 12.2% of Serbian households experienced catastrophic health spending in 2019, with medicines a major burden for poorer households.
This is where policy could shape the next phase. Serbia’s entry into the EU’s EU4Health programme from 2026 opens access for Serbian public and private healthcare entities to EU health funding, including areas such as diagnosis, treatment, cancer, cardiovascular disease, digital health, mental health and cross-border health threats. That does not automatically transform the private market, but it increases the importance of compliance, digital readiness, clinical standards, data governance and project-finance discipline.
The likely direction is not wholesale privatisation of Serbian healthcare. It is a layered system in which the public sector remains dominant in entitlement and funding, while private platforms capture the profitable pressure points: diagnostics, faster specialist access, corporate health, elective procedures, laboratories, premium outpatient care and selected hospital services. The investment premium will go to networks that can combine brand trust, doctor access, insurance contracts, location density, digital booking, standardised pricing and clinical governance.
For Serbia, the question is whether private capital becomes a release valve for a strained public system or a parallel system available mainly to those who can pay. For equity investors, the answer is already clearer: Serbia has moved from fragmented private medicine into a consolidating healthcare-platform market, and the next winners will be those that control not only beds and clinics, but the recurring flow of insured patients, corporate contracts, diagnostics and data.
